Preclinical studies of the novel vascular disrupting agent MN-029

  • Anticancer Res. 2005 Nov-Dec;25(6B):3899-904.
Wenyin Shi  1 ,  Dietmar W Siemann
Affiliations
  • 1. Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA.
PMID: 16309177
Abstract

Background: Vascular disrupting agents (VDAs) are designed to cause a rapid and selective shutdown of the established tumor vasculature, which leads to secondary ischemic tumor cell death.

Materials and methods: We examined the efficacy of a novel VDA, MN-029, in the rodent KHT sarcoma model.

Results: A significant reduction in the functional vessel number was observed after intraperitoneal injection of MN-029 at a dose of 100 mg/kg. Histological evaluation showed extensive necrosis (approximately 90%) by 24 h. MN-029 treatment to the tumor-bearing mice also resulted in a dose-dependent tumor cell killing. When used in combination with radiation or cisplatin chemotherapy, a 100 mg/kg dose of MN-029 significantly enhanced tumor killing compared to that seen with radiation or cisplatin alone.

Conclusion: The results demonstrated that MN-029 could cause rapid vascular shutdown in solid tumors, dose-dependent secondary tumor cell killing, and effective enhancement of the antitumor effects of radiation and cisplatin chemotherapy.

Products